Study Evaluates Artificial Pancreas Smartphone Application
Introduction to Artificial Pancreas Systems
A recent study has examined the effectiveness of an artificial pancreas smartphone application. Artificial pancreas systems serve as valuable tools for monitoring glucose levels in individuals with type 1 diabetes, ensuring that glucose levels remain within a safe range. However, challenges exist, including the speed of error detection and the level of trust users place in these devices.
Development of the iAPS
Deshpande and colleagues have introduced a new smartphone application for artificial pancreas systems, known as the interoperable artificial pancreas system (iAPS). This application is designed to enhance usability compared to traditional models that necessitate separate devices for system control, which can be inconvenient for users. The study, published in the journal Diabetes Technology and Therapeutics, received FDA approval and aimed to assess the functionality of this technology in human patients.
Features of the iAPS
The iAPS app establishes a wireless connection with continuous glucose monitors, insulin pump devices, and algorithms. It is based on an earlier artificial pancreas technology that operated on laptops and tablets but is now optimized for smartphones and available securely on Google Play. The app incorporates extensive security features and is compatible with two types of insulin pumps and Dexcom models (G5 and G6), providing versatile device integration. Its user-friendly interface includes checks and balances for system errors, remote monitoring capabilities, and advanced algorithms for enhanced safety.
Clinical Evaluation of iAPS
The clinical evaluation of the artificial pancreas system involved a pilot study conducted in Santa Barbara, California, with six participants aged between 18 and 75, all of whom had diabetes and utilized insulin pumps. This evaluation occurred over 48 hours and included deliberate challenges to test the system’s robustness, such as consuming large meals at restaurants, late-night ice cream, and experiencing intentional loss of connection. The study commenced on day one at 5:00 p.m. and concluded on day three at the same time. To ensure patient safety, independent glucose tests were performed at scheduled intervals or upon user request.
Results of the Study
In comparison to sensor-augmented pumps (SAP), the study indicated that participants spent less time below the glucose target range and, notably, spent a longer duration within the target range. There were fewer instances of hypoglycemia, and no hyperglycemic events were reported. Despite interruptions, the system maintained reliability, even while participants used the study phones for other activities such as texting and watching videos.
Conclusion and Future Research Directions
In summary, the artificial pancreas app demonstrated effective performance in a monitored, simulated real-life setting among human participants over a brief 48-hour period. However, the study’s limitations include its short duration, small sample size, and the presence of clinical and technical support staff, which may not reflect real-world conditions. Future research will need to focus on further modifications to the app and conduct additional trials.
Author Information
Written by Olajumoke Marissa Ologundudu B.Sc. (Hons)
Reference
Deshpande S et al. Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development. Diabetes Technology and Therapeutics. 2019;21(1). doi: 10.1089/dia.2018.0278.